CN118284606A - 作为GABAA α5受体调节剂的双环胺衍生物 - Google Patents

作为GABAA α5受体调节剂的双环胺衍生物 Download PDF

Info

Publication number
CN118284606A
CN118284606A CN202280074314.9A CN202280074314A CN118284606A CN 118284606 A CN118284606 A CN 118284606A CN 202280074314 A CN202280074314 A CN 202280074314A CN 118284606 A CN118284606 A CN 118284606A
Authority
CN
China
Prior art keywords
methyl
methoxy
tetrahydro
naphthyridine
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280074314.9A
Other languages
English (en)
Chinese (zh)
Inventor
G·斯扎博
A·波托尔
P·艾尔德尔伊
I·巴塔
G·I·图罗斯
G·L·卡普斯
O·埃利拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of CN118284606A publication Critical patent/CN118284606A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202280074314.9A 2021-09-29 2022-09-28 作为GABAA α5受体调节剂的双环胺衍生物 Pending CN118284606A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP2100338A HU231691B1 (hu) 2021-09-29 2021-09-29 GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
HUP2100338 2021-09-29
PCT/IB2022/059214 WO2023053015A1 (en) 2021-09-29 2022-09-28 BICYCLIC AMINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS

Publications (1)

Publication Number Publication Date
CN118284606A true CN118284606A (zh) 2024-07-02

Family

ID=89993434

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280074314.9A Pending CN118284606A (zh) 2021-09-29 2022-09-28 作为GABAA α5受体调节剂的双环胺衍生物

Country Status (21)

Country Link
US (1) US20250051323A1 (enExample)
EP (1) EP4408842A1 (enExample)
JP (1) JP2024536039A (enExample)
KR (1) KR20240089056A (enExample)
CN (1) CN118284606A (enExample)
AR (1) AR127182A1 (enExample)
AU (1) AU2022357572A1 (enExample)
CA (1) CA3231776A1 (enExample)
CL (1) CL2024000893A1 (enExample)
CO (1) CO2024005424A2 (enExample)
CU (1) CU20240013A7 (enExample)
EC (1) ECSP24032316A (enExample)
GE (2) GEAP202416510A (enExample)
HU (1) HU231691B1 (enExample)
IL (1) IL311640A (enExample)
JO (1) JOP20240057A1 (enExample)
MX (1) MX2024003812A (enExample)
PE (1) PE20240816A1 (enExample)
TW (1) TW202330518A (enExample)
WO (1) WO2023053015A1 (enExample)
ZA (1) ZA202403230B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024251133A1 (zh) * 2023-06-05 2024-12-12 武汉人福创新药物研发中心有限公司 作为α5-GABAA受体调节剂的杂环化合物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230518B1 (hu) 2005-12-20 2016-10-28 Richter Gedeon Nyrt. Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények
HUP0600810A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
HUP0600808A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0600809A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
US8742097B2 (en) 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
KR20150033679A (ko) 2012-06-26 2015-04-01 사니오나 에이피에스 페닐 트리아졸 유도체 및 이의 gabaa 수용체 복합체 조절용 용도
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
HUP1300139A2 (en) 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
CN112409363B (zh) 2013-12-20 2023-11-14 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
PT3439665T (pt) 2016-03-18 2022-09-27 Uwm Res Foundation Inc Tratamento de sintomas cognitivos e de humor em distúrbios neurodegenerativos e neuropsiquiátricos com gaba contendo agonistas de recetores de gabaa contendo alfa5
UA125524C2 (uk) 2016-12-08 2022-04-13 Ф. Хоффманн-Ля Рош Аг Ефірні похідні ізоксазолу як позитивні алостеричні модулятори рецептора гамк а альфа-5
HU231058B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt. Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素V1a受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
AU2019286312B2 (en) 2018-06-13 2023-08-17 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as GABA A alpha5 PAM
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231478B1 (hu) 2018-07-13 2024-02-28 Richter Gedeon Nyrt. Szubsztituált (aza)indol származékok
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) * 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
TWI901650B (zh) * 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物

Also Published As

Publication number Publication date
JP2024536039A (ja) 2024-10-04
TW202330518A (zh) 2023-08-01
WO2023053015A1 (en) 2023-04-06
GEAP202416510A (en) 2024-08-12
CU20240013A7 (es) 2024-11-15
JOP20240057A1 (ar) 2024-03-20
CA3231776A1 (en) 2023-04-06
HUP2100338A1 (hu) 2023-04-28
IL311640A (en) 2024-05-01
GEP20257812B (en) 2025-10-27
MX2024003812A (es) 2024-04-25
CO2024005424A2 (es) 2024-05-10
ECSP24032316A (es) 2024-05-31
ZA202403230B (en) 2024-12-18
KR20240089056A (ko) 2024-06-20
HU231691B1 (hu) 2025-10-28
AR127182A1 (es) 2023-12-27
PE20240816A1 (es) 2024-04-18
EP4408842A1 (en) 2024-08-07
CL2024000893A1 (es) 2024-09-06
AU2022357572A1 (en) 2024-05-02
US20250051323A1 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
KR20150027267A (ko) LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘
TW202124386A (zh) 唑稠合之嗒-3(2h)-酮衍生物
JP2003516989A (ja) Gaba受容体リガンドとしてのピラゾロ−ピリジン誘導体
AU2015249497A1 (en) Heteroaromatic compounds and their use as dopamine D1 ligands
EP3856342B1 (en) Bicyclic derivatives as gabaa a5 receptor modulators
EP4126858B1 (en) Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
WO2004014891A1 (en) Pyridazine derivatives as ligands for gaba receptors
JP7805946B2 (ja) GABA Aアルファ5受容体調節剤としてのナフチリジンおよびピリド[3,4-c]ピリダジン誘導体
TW202330518A (zh) 作為GABAA α5受體調節劑之雙環胺衍生物
WO2015166366A1 (en) Heterocyclic compounds and their use as dopamine d1 ligands
EA052124B1 (ru) БИЦИКЛИЧЕСКИЕ АМИНОПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ α5 РЕЦЕПТОРОВ GABAA
EA049237B1 (ru) ПРОИЗВОДНЫЕ НАФТИРИДИНА И ПИРИДО[3,4-c]ПИРИДАЗИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ АЛЬФА 5 РЕЦЕПТОРОВ GABAA
EA053259B1 (ru) Конденсированные с азолом производные пиридазин-3(2н)-она

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination